1 recruiting, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Fludarabine (Conditional therapy): new trials by email Literature Review of Fludarabine (Conditional therapy) trials Research Report on Fludarabine (Conditional therapy)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies DuoCAR20.19.22-D95, Fludarabine (Conditional therapy), Cyclophosphamide (Conditional therapy) - B-Cell Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | University of Kansas Medical Center | 54 | 2025-03-31 | 2026-05-14 |
| A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug) - Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Terminated | CARGO Therapeutics | 101 | 2023-08-01 | 2025-05-15 |
Lymphoma, B-Cell (2) · Burkitt Lymphoma (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1)
CARGO Therapeutics (1) · University of Kansas Medical Center (1)
United States (2)